Adjuvant radiotherapy omission with maintenance immunotherapy appears to be a safe and patient-beneficial strategy for OSCC patients achieving pCR after NICT. The integrated TP53/B-cell biomarker model provides preliminary evidence for personalizing this de-escalation approach.
Guan et al. (Wed,) studied this question.